Abstract
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), resulting in right ventricular failure and death. Primary treatment of PAH (Class 1) is based on the use of four classes of drugs in the form of monotherapy or combination therapy. Despite significant advances in drug‐based treatment of PAH and improvements in survival rates, the prognosis for PAH patients remains poor. PAH drugs target mechanisms involved in vasodilation of pulmonary arterial vessels (Fig. 1A), but their vascular effects are not limited to the pulmonary circulation, probably contributing to side effects and limiting drug efficacy. Thus, there is a need for additional therapeutic approaches.
Original language | English |
---|---|
Pages (from-to) | 470-471 |
Number of pages | 2 |
Journal | Respirology |
Volume | 25 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- oxygen therapy
- pulmonary hypertension